The Role of CONUT Score as a Prognostic Indicator in Progressive Pulmonary Fibrosis: An Accessible Tool for Clinical Risk Assessment - Report - MDSpire

The Role of CONUT Score as a Prognostic Indicator in Progressive Pulmonary Fibrosis: An Accessible Tool for Clinical Risk Assessment

  • By

  • Esma Sevil Akkurt

  • Tugce Sahin Ozdemirel

  • Berna Akıncı Ozyurek

  • Kerem Ensarioglu

  • Ozlem Duvenci Birben

  • Esma Zenbilli

  • November 18, 2025

  • 0 min

Share

Clinical Report: The Role of CONUT Score as a Prognostic Indicator in PPF

Overview

The CONUT score, derived from serum albumin, total cholesterol, and lymphocyte count, serves as a prognostic indicator in patients with progressive pulmonary fibrosis (PPF). This study highlights its potential utility in clinical risk assessment and patient management.

Background

Progressive pulmonary fibrosis (PPF) is a severe form of fibrosing interstitial lung disease that leads to significant morbidity and mortality. Identifying patients at risk for a progressive fibrotic course is crucial for timely intervention. Nutritional status, as assessed by the CONUT score, may provide valuable prognostic information in this patient population.

Data Highlights

This study included 58 patients diagnosed with PPF, followed for a minimum of six months. The CONUT score was calculated based on serum albumin, total cholesterol, and lymphocyte count, with scores indicating varying degrees of nutritional status.

Key Findings

  • The CONUT score is a simple tool that can be calculated from routine laboratory tests.
  • Higher CONUT scores correlate with poorer nutritional status and may predict adverse outcomes in PPF patients.
  • Patients with moderate to severe malnutrition (CONUT scores >4) had worse prognoses compared to those with normal nutritional status.
  • The study supports the use of the CONUT score in clinical practice for risk stratification in PPF.
  • Multidisciplinary evaluations were employed to ensure comprehensive patient assessment and management.

Clinical Implications

The CONUT score can be integrated into routine clinical assessments to identify patients with PPF at higher risk for adverse outcomes. This tool may facilitate early interventions aimed at improving nutritional status and overall prognosis.

Conclusion

The CONUT score is a promising prognostic tool for assessing nutritional status in patients with progressive pulmonary fibrosis, potentially guiding clinical decision-making and improving patient outcomes.

References

  1. BMC Pulmonary Medicine, 2025 -- CONUT score as a prognostic biomarker in progressive pulmonary fibrosis
  2. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline - PMC
  3. Bone Marrow Transplantation — Validation of the Concise Objectifiable Risk Evaluation (CORE) score across multiple centers confirms its role in enhancing the Hematopoietic Cell Comorbidity Index (HCT-CI)
  4. The New Gastroenterologist — Enhanced Risk Assessment Tool May Optimize HCC Monitoring in Cirrhosis Patients
  5. European Radiology — Utilizing Chest CT Biomarkers for Identifying High-Risk COVID-19 Patients: Insights from a Retrospective Multicenter Analysis
  6. Assessing the Risk of Postoperative Pancreatic Fistula Following Pancreatic Head Resection: Which Scoring System is Most Effective?
  7. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline - PMC
  8. Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON - PubMed
  9. CONUT score as a prognostic biomarker in progressive pulmonary fibrosis: a simple tool for clinical risk stratification | BMC Pulmonary Medicine | Springer Nature Link

Original Source(s)

Related Content